Enveda raises $311 million for nature-derived AI drugs

Enveda, a biotechnology startup using artificial intelligence to discover drugs from plants and microbes, raised $311 million in a Series E round at a $2 billion valuation. This funding aims to accelerate the company's process of advancing AI-discovered drug candidates into human clinical trials.